SINDER TECH Files for Listing on HKEX: China's Tenth-Largest Animal Health Company by 2025 Revenue

NewTimeSpace News: According to the Hong Kong Stock Exchange disclosure on 14 October 2026, Shandong Sinder Technology Co., Ltd. has filed an application with the Main Board of the Hong Kong Stock Exchange for listing, marking the Company's second application. Zotai International acts as its sole sponsor. Founded in 1999, the Company is an animal health enterprise principally engaged in the research and development, manufacture and sale of a full range of animal health and ancillary products, covering veterinary biological products such as vaccines, antibodies and transfer factors, traditional Chinese veterinary medicines, chemical preparations, feed and feed additives, enabling the prevention, diagnosis, treatment and control of diseases in poultry, livestock, aquatic animals and pets. The prospectus stated that during the Track Record Period, most of the Company's revenue was generated from sales of animal health and ancillary products.

The prospectus stated that according to CIC, by2025 revenue, the Company was the tenth-largest domestic and overseas manufacturer in China's animal health market and ranked among the top three in China's poultry veterinary biological products market. As of the 2025 financial year, utilisation rate of the antibody, transfer factor and inactivated vaccine production lines was approximately 90.0%; the Company had four major production bases, 34 production lines certified under GMP for veterinary drugs and 323 veterinary drug product approval numbers, all as at the Latest Practicable Date. On the customer side, as at 31 May 2026, the Company had over 6,800 customers and 321 distributors, with a customer retention rate of 68.2% in the 2025 financial year, and mature cooperation relationships with large poultry and livestock farms spanning over 10 years.

The prospectus stated that the Company's revenue for the 2023, 2024 and 2025 financial years and the five months ended May 2026 was RMB 984.6 million, RMB 981.8 million, RMB 1,194.3 million and RMB 507.2 million respectively, with gross profit margins of 46.3%, 46.0%, 49.3% and 49.7% respectively. Export sales in the 2025 financial year increased by RMB 38.5 million compared with the 2024 financial year, up 136.2%.